Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CRBU
CARIBOU BIOSCIENCES, INC.
NASDAQ
$1.62
▼ DOWN 2.41% (-0.04)

KEY STATISTICS

Market Cap$160.67 M
52w High$3.54
52w Low$1.38
Dividend Yield—
Frequency—
P/E-1.50
Volume666.56K
Shares Out.99.18M

COMPANY

LEADERSHIP

Rachel E. Haurwitz
CHIEF EXECUTIVE
Rachel E. Haurwitz

COMPENSATION 2026

Salary$667,534
Stock Awards$192,818
Incentive Plan Pay$0
All Other Comp.$14,000
Total$1,840,965

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 23, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
97

PRICE TARGET

Target High$7.00
Target Low$3.00
Target Median$5.00
Target Consensus$5.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$2.18M
NOV
11
WED

PRICE

$1.62 ▼ DOWN 2.41% (−$0.04)
$1.60$1.62$1.64$1.669:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.62

About Caribou Biosciences, Inc.

https://cariboubio.com ↗

Caribou Biosciences is a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies for hematologic cancers and solid tumors, with lead programs including anti-CD19, anti-BCMA, and anti-CD371 CAR-T therapies.

INDUSTRY

Biotechnology

A PRODUCT CARIBOU BIOSCIENCES, INC. IS KNOWN FOR

CB-010 (vispacabtagene regedleucel)
CB-010 (vispacabtagene regedleucel)

CB-010 (vispa-cel) is Caribou Biosciences' allogeneic CAR-T therapy with PD-1 knockout, targeting relapsed/refractory B cell non-Hodgkin lymphoma and aiming to enhance anti-tumor persistence.

COMPETITORS

COMPETITOR
ALLO COMPARE
ATRA COMPARE
BEAM COMPARE
CLLS COMPARE
FATE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment$2.2M $3.94M ▲$2.4M ▼$1.5M ▼

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$1.82M $3.77M ▲$2.26M ▼$1.49M ▼
NonUS$377K $170K ▼$140K ▼$7K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
61
LISTED HERE
12
RANKED BY POSITION SIZE
VTI
0.00% · 3.0M
IWM
0.00% · 2.3M
SCHA
0.00% · 421.4K
FESM
0.01% · 322.1K
DFAS
0.00% · 255.3K
NXTE
0.65% · 210.2K
OMFS
0.09% · 165.5K
GSSC
0.02% · 152.4K
AVSC
0.01% · 140.6K
GNOM
0.15% · 86.9K
XRS2.F
0.00% · 86.1K
URTY
0.00% · 3.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
34.86%
HOLDERS
166
TOP 12 OF 166 · RANKED BY POSITION SIZE
Blackrock Inc.
6.9M sh · $11.39M
Pfizer Inc
4.7M sh · $8.35M
Vanguard Group Inc
4.3M sh · $6.84M
Millennium Management LLC
3.2M sh · $7.49M
Kynam Capital Management, LP
3.1M sh · $7.15M
Renaissance Technologies LLC
2.6M sh · $4.92M
Blackrock, Inc.
2.1M sh · $4.07M
Pictet Asset Management SA
1.8M sh · $7.69M
Two Sigma Investments, LP
1.8M sh · $3.34M
Abrdn Plc
1.4M sh · $2.21M
Pfm Health Sciences, LP
1.4M sh · $3.17M
Bank Of America Corp /De/
1.3M sh · $2.46M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF TECHNOLOGY OFFICER
Kelly Timothy P
Sale · 6.2K shares
2026-02-25
★
OFFICER: CHIEF TECHNOLOGY OFFICER
Kelly Timothy P
Purchase · 45.0K shares
2026-02-20
★
OFFICER: CHIEF TECHNOLOGY OFFICER
Kelly Timothy P
Sale · 3.1K shares
2026-02-24
★
OFFICER: CHIEF LEGAL OFFICER
MCCLUNG BARBARA G
Purchase · 202.5K shares
2026-02-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
B of A Securities BUY HC Wainwright & Co. BUY Evercore ISI Group OUTPERFORM Citigroup BUY

SECTORS PEERS

PEERPRICE
ALLO$2.02COMPARE
PRLD$5.47COMPARE
ENTA$13.60COMPARE
FHTX$6.00COMPARE
OBIO$5.18COMPARE
IVA$4.71COMPARE
PYXS$3.23COMPARE
TNYA$0.69COMPARE